Mirna Therapeutics, a clinical-stage biotech developing microRNA replacement therapies for cancer, announced terms for its IPO on Friday.
The Austin, TX-based company plans to raise $65 million by offering 4.7 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Mirna Therapeutics would command a fully diluted market value of $241 million.
Mirna Therapeutics, which was founded in 2007, plans to list on the Nasdaq under the symbol MIRN. Citi and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of September 28, 2015.
